References
1. Recent surveillance data. Centers for Disease Control and Prevention. Reviewed April 29, 2021. Accessed June 4, 2021. https://www.cdc.gov/lyme/datasurveillance/recent-surveillance-data.html
2. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Care Res (Hoboken). 2021;73(1):1-9. doi:10.1002/acr.24495
3. How many people get Lyme disease? Centers for Disease Control and Prevention. Reviewed January 13, 2021. Accessed May 12, 2021. https://www.cdc.gov/lyme/stats/humancases.html
4. Diseases transmitted by ticks. Centers for Disease Control and Prevention. Reviewed April 2, 2020. Accessed April 7, 2021. https://www.cdc.gov/ticks/diseases/index.html
5. Centers for Disease Control and Prevention. Tickborne Diseases of the United States: A Reference Manual for Health Care Providers. 4th ed. Centers for Disease Control and Prevention; 2017. Accessed April 20, 2021. https://www.cdc.gov/ticks/tickbornediseases/index.html
6. Symptoms of tickborne illness. Centers for Disease Control and Prevention. Reviewed January 10, 2019. Accessed May 12, 2021. https://www.cdc.gov/ticks/symptoms.html
7. Murray TS, Shapiro ED. Lyme disease. Clin Lab Med. 2010;30(1)311-328. doi:10.1016/j.cll.2010.01.003
8. What you need to know about Borrelia mayonni. Centers for Disease Control and Prevention. Reviewed September 12, 2019. Accessed April 20, 2021. https://www.cdc.gov/lyme/mayonii/index.html
9. Signs and symptoms of untreated Lyme disease. Centers for Disease Control and Prevention. Reviewed January 15, 2021. Accessed April 20, 2021. https://www.cdc.gov/lyme/signs_symptoms/index.html
10. Telford SR III, Goethert HK, Molloy PJ, et al. Borrelia miyamotoi disease: neither Lyme disease nor relapsing fever. Clin Lab Med. 2015;35(4):867-882. doi:10.1016/j.cll.2015.08.002
11. Lyme carditis. Centers for Disease Control and Prevention. Reviewed October 26, 2020. Accessed April 20, 2021. https://www.cdc.gov/lyme/treatment/lymecarditis.html
12. Neurologic Lyme disease. Centers for Disease Control and Prevention. Reviewed October 23, 2020. Accessed April 20, 2021. https://www.cdc.gov/lyme/treatment/NeurologicLyme.html
13. Lyme arthritis. Centers for Disease Control and Prevention. Reviewed October 26, 2020. Accessed April 20, 2021. https://www.cdc.gov/lyme/treatment/LymeArthritis.html
14. Schoen RT. Lyme disease: diagnosis and treatment. Curr Opin Rheumatol. 2020;32(3):247-254. doi:10.1097/BOR.0000000000000698
15. Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep. 2019;68(32):703. doi:10.15585/mmwr.mm6832a4
16. Diagnosis and testing. Centers for Disease Control and Prevention. Reviewed November 20, 2019. Accessed April 20, 2021. https://www.cdc.gov/lyme/diagnosistesting/index.html
17. Kalish RA, McHugh G, Granquist J, et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis. 2001;33(6):780-785. doi:10.1086/322669
18. Steere AC. Treatment of Lyme arthritis. J Rheumatol. 2019;46(8):871-873. doi:10.3899/jrheum.190320
19. Post-treatment Lyme disease syndrome. Centers for Disease Control and Prevention. Reviewed November 8, 2019. Accessed April 20, 2021. https://www.cdc.gov/lyme/postlds/index.html
20. Ścieszka J, Dąbek J, Cieślik P. Post-Lyme disease syndrome. Reumatologia. 2015;53(1):46-48. doi:10.5114/reum.2015.50557
Models used for illustrative purposes only.
Published date: June 2021